Top

Published in:

Open Access 01-12-2011 | Review

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6^th-7 ^th2010"

Authors: Paolo A Ascierto, Eleonora De Maio, Stefano Bertuzzi, Giuseppe Palmieri, Ruth Halaban, Mary Hendrix, Mohamed Kashani-sabet, Soldano Ferrone, Ena Wang, Alistair Cochran, Licia Rivoltini, Peter P Lee, Bernard A Fox, John M Kirkwood, Claudio Dansky Ullmann, Frederic F Lehmann, Mario Sznol, Douglas J Schwartzentruber, Michele Maio, Keith Flaherty, Jerome Galon, Antoni Ribas, James Yang, David F Stroncek, Nicola Mozzillo, Franco M Marincola

Published in: Journal of Translational Medicine | Issue 1/2011

Abstract

Progress in understanding the molecular basis of melanoma has made possible the identification of molecular targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from basic science and it will be important to implement their rapid translation into clinical practice by active clinical investigation.

The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy) and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010.

This international congress gathered more than 30 international and Italian faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-23. 10.1056/NEJMoa1003466.PubMedCentralCrossRefPubMed

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010, 363: 809-19. 10.1056/NEJMoa1002011.PubMedCentralCrossRefPubMed

Lane J, Bertuzzi S: Measuring the Results of Science Investments. Science. 2011, 331: 678-80. 10.1126/science.1201865.CrossRefPubMed

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Allen RE, Singer MI, Leong SPL, Ljung B-M, Sagebiel RW, Kashani-Sabet M: The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 2005, 102: 6092-7. 10.1073/pnas.0501564102.PubMedCentralCrossRefPubMed

Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR, Sagebiel RW: A multi-marker assay to distinguish benign nevi from malignant melanomas. Proc Natl Acad Sci USA. 2009, 106: 6268-72. 10.1073/pnas.0901185106.PubMedCentralCrossRefPubMed

Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SPL, Miller JR, Sagebiel RW, Kashani-Sabet M: Prognostic significance of NCOA3 overexpression in primary cutaneous melanoma. J Clin Oncol. 2006, 24: 4565-9. 10.1200/JCO.2006.07.3833.CrossRefPubMed

Kashani-Sabet M, Venna S, Rangel J, Nosrati M, Sucker A, Egberts F, Baehner FL, Simko J, Leong SPL, Haqq C, Hauschild A, Schadendorf A, Miller JR, Sagebiel RW: A multi-marker prognostic assay for melanoma. Clin Cancer Res. 2009, 15: 6987-92. 10.1158/1078-0432.CCR-09-1777.PubMedCentralCrossRefPubMed

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007, 25: 2546-53. 10.1200/JCO.2006.08.5829.CrossRefPubMed

Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP: Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007, 4: e176-10.1371/journal.pmed.0040176.PubMedCentralCrossRefPubMed

10.

Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP: Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA. 2009, 106: 9010-5. 10.1073/pnas.0901329106.PubMedCentralCrossRefPubMed

11.

Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM: Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009, 27: 38-44. 10.1200/JCO.2008.17.1777.PubMedCentralCrossRefPubMed

12.

Van Den Eynde BJ, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol. 1997, 9: 684-93. 10.1016/S0952-7915(97)80050-7.CrossRefPubMed

13.

Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G: Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer. 2003, 39: 70-7. 10.1016/S0959-8049(02)00479-3.CrossRefPubMed

14.

Kruit WH, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Brichard V, Spatz A, Eggermont A, Keilholz U, Lehmann F: Immunization with the recombinant MAGE-A3 protein combined with Adjuvant Systems AS02B or AS15 in patients with metastatic melanoma: final results of a Phase II study of the EORTC Melanoma Group [abstract]. Perspectives in Melanoma. 2009, 0-0001.

15.

Spatz A, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Louahed J, Peeters O, Lejeune D, Brichard VG, Eggermont A, Keilholz U, Lehmann F: MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI) clinical activity in metastatic melanoma is associated with predictive biomarkers present in the tumor prior to immunization [abstract]. Canadian Melanoma Conference. 2010, [http://www.buksa.com/melanoma/docs/2010-FinalProgram.pdf]

16.

Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Esteban E, Malinowski W, Jassem J, Passlick B, Lopez Brea M, Debruyne C: Phase II randomized study of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC): 44 month follow-up, humoral and cellular immune response data [abstract]. 2008, ESMO-IASLC Congress, 148O-

17.

Louahed J, Lehmann F, Ulloa-Montoya F, Gruselle O, Dizier B, Vansteenkiste J, Kruit W, Brichard V: Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment [abstract]. Molecular Cancer Therapeutics. 2009, 8 (12 supplements): 1-

18.

Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, Gailani F, Riley LB, Vena D, Hwu P: A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol. 2009, 27: 18s-CrossRef

19.

Ascierto PA, Streicher HZ, Sznol M: Melanoma: a model for testing new agents in combination therapies. J Transl Med. 2010, 8: 38-10.1186/1479-5876-8-38.PubMedCentralCrossRefPubMed

20.

Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353: 2654-66.CrossRefPubMed

21.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Pages F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-4. 10.1126/science.1129139.CrossRefPubMed

22.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J: Histopathological-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol.

23.

Galon J, Fridman WH, Pages F: The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007, 67: 1883-6. 10.1158/0008-5472.CAN-06-4806.CrossRefPubMed

24.

Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J: Natural immunity to cancer in humans. Curr Opin Immunol. 2010, 22: 215-22. 10.1016/j.coi.2010.02.006.CrossRefPubMed

25.

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J: Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010, 138: 1429-40. 10.1053/j.gastro.2009.10.057.CrossRefPubMed

26.

Pages F, Kirilovsky A, Mlecnik B, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman W-H, Galon J: The in situ cytotoxic and memory T cells predict outcome in early-stage colorectal cancer patients. J Clin Oncol. 2009, 27: 5944-51. 10.1200/JCO.2008.19.6147.CrossRefPubMed

27.

Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996, 77: 1303-10. 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5.CrossRefPubMed

28.

Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH: Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010, 29: 1093-102.CrossRefPubMed

Title: Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6 th -7 th 2010"
Authors: Paolo A Ascierto
Eleonora De Maio
Stefano Bertuzzi
Giuseppe Palmieri
Ruth Halaban
Mary Hendrix
Mohamed Kashani-sabet
Soldano Ferrone
Ena Wang
Alistair Cochran
Licia Rivoltini
Peter P Lee
Bernard A Fox
John M Kirkwood
Claudio Dansky Ullmann
Frederic F Lehmann
Mario Sznol
Douglas J Schwartzentruber
Michele Maio
Keith Flaherty
Jerome Galon
Antoni Ribas
James Yang
David F Stroncek
Nicola Mozzillo
Franco M Marincola
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-9-32

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6^th-7 ^th2010"

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil

Trauma is danger

Erratum to Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA - a mechanism involved in SERPINE1 (PAI-1) overexpression

Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with Hereditary Ataxia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page